LL37 (14-21)+Indolicidin (5-13), LI

General Information


DCTPep ID  DCTPep01918

Peptide Name   LL37 (14-21)+Indolicidin (5-13), LI

Sequence  GKEFKRIVKWPWWPWRR

Sequence Length  17

UniProt ID  P49913  P33046 

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

ACP Tumor active peptide Membrane-targeted



Activity Information


Cell Line Disease Activity Assay Testing Time Literature
Hep-G2 Hepatoblastoma 87.5% Killing=128µM MTT assay 20-24 h 1

Hemolytic Activity  Human erythrocytes: 5%Hemolysis>128 µM

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available



Structure Information


PDB ID  Not available

Predicted Structure  DCTPep01918

(Please note that there is the predicted structure, predicted by AlphaFold)

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Amidation

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C117H167N33O20

Absent amino acids  ACDHLMNQSTY

Theoretical pI  11.73

Acidic residues  1

Basic residues  6

Polar residues  1

Molecular weight (Average)  2355.82

Molecular weight (Monoisotopic)  2354.31

Common amino acids  W

Net charge  5

Instability index (II)  38.37

Aliphatic index  40.00

Grand average of hydropathicity (GRAVY)  -1.435

Half Life 
  30 hours (mammalian reticulocytes, in vitro).
  >20 hours (yeast, in vivo).
  >10 hours (Escherichia coli, in vivo).

Extinction coefficients 
  Ext. coefficient 22000
  Abs 0.1% (=1 g/l) 9.339

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 29282543

Title  Characterization of bactericidal efficiency, cell selectivity, and mechanism of short interspecific hybrid peptides

Doi 10.1007/s00726-017-2531-1

Year  2018

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DBAASP ID  DBAASPS_11172

DCTPep is developed by Dr.Zheng's team.